Last reviewed · How we verify

NCT03863691

Influence of Dopaminergic Blockade on Stress Responses, Motivation and Emotional Reactivity in Humans.

Completed NA Last updated 21 September 2020
What this trial tests

NA trial testing Amisulpride 300 MG in Healthy Participants in 85 participants. Completed in 15 July 2020.

Timeline
15 April 2019
Primary endpoint
15 July 2020
15 July 2020

Quick facts

Lead sponsorPhilipps University Marburg
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposebasic science
Enrollment85
Start date15 April 2019
Primary completion15 July 2020
Estimated completion15 July 2020
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Philipps University Marburg

Who can join

Adults 18 to 40, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to identify whether partial blockade of human dopamine signaling with antipsychotic drugs affects human stress responses, motivation and emotion. 84 healthy adult participants are planned to complete the study protocol. Therefore three experiments are planned: Experiment 1: Influence of amisulpride on human stress responses. Experiment 2: Influence of amisulpride on motivated effort. Experiment 3: Influence of amisulpride on emotion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

Other Philipps University Marburg trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03863691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing